Tag: ankylosing spondylitis industry demand

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Ankylosing Spondylitis Market Size Forecast: How Large Could The Market Become By 2030?

The ankylosing spondylitis market demonstrated robust expansion recently, with projections indicating a rise from $6.34 billion in 2025 to $6.85 billion in 2026, reflecting a compound annual growth rate of 8.0%. This historical growth trajectory was underpinned by heightened diagnostic recognition, broader accessibility to non-steroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs), enhanced provision of specialized rheumatology care, expanded access to hospital-based treatments, and the increasing utilization of diagnostic imaging for tracking disease progression.

The ankylosing spondylitis market is poised for substantial expansion over the coming years, projecting a rise to $9.42 billion by 2030 with a compound annual growth rate of 8.3%. This anticipated increase during the forecast period is propelled by several key factors, including a greater acceptance of biologic and biosimilar treatments, an escalating emphasis on individualized medical care, the broadening of sophisticated biologic drug development, a growing need for sustained management of the condition, and increased funding allocated to autoimmune disease research. Prominent developments expected within this timeframe involve a heightened utilization of biologic treatments, a more frequent application of disease-modifying antirheumatic drugs (DMARDs) designed for specific targets, a greater commitment to identifying the disease in its early stages, the advancement of tailored therapeutic strategies, and a more comprehensive incorporation of physical therapy into patient care plans.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11962&type=smp

Ankylosing Spondylitis Market Industry Drivers: What Is Driving Revenue Growth?

The projected expansion of the ankylosing spondylitis market is anticipated to be propelled by the rising occurrence of autoimmune conditions. These conditions encompass a wide array of disorders marked by an aberrant immune system response where the body’s own defenses erroneously attack and harm healthy cells, tissues, and organs. Ankylosing spondylitis, classified as an autoimmune disease, arises when the immune system incorrectly directs its activity towards the body’s own tissues, resulting in inflammation and subsequent damage. While a genetic susceptibility and environmental influences play a role in the pathogenesis of ankylosing spondylitis, a type of autoimmune arthritis predominantly impacting the spinal column and pelvic region, further data underscores this trend. Specifically, the Impact of IBD Report 2023, released in September 2023 by the IBD Clinical and Research Centre in Canada, highlighted that in 2023, inflammatory bowel disease (IBD) affected 825 individuals per 100,000, impacting over 320,000 Canadians. Moreover, with an anticipated annual prevalence increase of 2.44%, it is estimated that by 2035, 1.1% of the Canadian populace, equating to 470,000 individuals, will be managing IBD. Consequently, the escalating rates of autoimmune diseases are poised to fuel the forthcoming growth trajectory of the ankylosing spondylitis market.

Ankylosing Spondylitis Market Segmentation And Category Breakdown

The ankylosing spondylitis market covered in this report is segmented –

1) By Treatment Type: Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biological Therapies, Steroids, Physical Therapies, Surgery

2) By Molecule: Biologics, Biosimilar, Small Molecules

3) By Route Of Administration: Parenteral, Oral, Other Routes

4) By Application: Juveniles, Adults

5) By End User: Hospitals, Clinics

Subsegments:

1) By Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Over-The-Counter NSAIDs, Prescription NSAIDs

2) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional DMARDs, Targeted DMARDs

3) By Biological Therapies: TNF Inhibitors, IL-17 Inhibitors

4) By Steroids: Oral Steroids, Injectable Steroids

5) By Physical Therapies: Physiotherapy, Exercise Programs

6) By Surgery: Joint Replacement Surgery, Spinal Surgery

#Ankylosing Spondylitis Market Growth Trends: What Is Influencing The Future Outlook?

Within the ankylosing spondylitis market, leading corporations are concentrating their efforts on creating cutting-edge biologic treatments, including biosimilars, with the aims of improving patient accessibility, lowering healthcare expenditures, and offering established delivery methods. These biosimilars are medications that utilize the same active components as original biologic drugs but are designed to be just as effective and safe. To illustrate, in August 2025, Amgen Biotechnology Singapore, a biotechnology enterprise situated in Singapore, secured approval for its adalimumab biosimilar, known as Amgevita, available in both a 40 mg/0.4 mL autoinjector and a 20 mg/0.2 mL prefilled syringe. This treatment is prescribed to alleviate the signs and symptoms experienced by adult individuals suffering from active ankylosing spondylitis who have not responded adequately to standard treatments. This approach facilitates well-known administration pathways, capitalizes on a recognized active compound, and introduces a more economically viable choice within the biologics sector.

Ankylosing Spondylitis Market Competitive Analysis Of Major Industry Participants

Major companies operating in the ankylosing spondylitis market are Pfizer Inc., Johnson & Johnson Pvt. Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Viatris Inc., Astellas Pharma Inc., AstraZeneca plc, UCB Inc., Cipla Inc., Zydus Lifesciences Limited, Celltrion Inc., Hetero Labs Ltd., Janssen Biotech Inc., Reliance Life Sciences Pvt. Ltd.

Access The Complete Ankylosing Spondylitis Market Report:

https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report

Ankylosing Spondylitis Market Geographic Landscape: Which Region Dominates Industry Growth?

North America was the largest region in the ankylosing spondylitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ankylosing spondylitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Ankylosing Spondylitis Market Size Forecast: How Large Could The Market Become By 2030?

The ankylosing spondylitis market demonstrated robust expansion recently, with projections indicating a rise from $6.34 billion in 2025 to $6.85 billion in 2026, reflecting a compound annual growth rate of 8.0%. This historical growth trajectory was underpinned by heightened diagnostic recognition, broader accessibility to non-steroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs), enhanced provision of specialized rheumatology care, expanded access to hospital-based treatments, and the increasing utilization of diagnostic imaging for tracking disease progression.

The ankylosing spondylitis market is poised for substantial expansion over the coming years, projecting a rise to $9.42 billion by 2030 with a compound annual growth rate of 8.3%. This anticipated increase during the forecast period is propelled by several key factors, including a greater acceptance of biologic and biosimilar treatments, an escalating emphasis on individualized medical care, the broadening of sophisticated biologic drug development, a growing need for sustained management of the condition, and increased funding allocated to autoimmune disease research. Prominent developments expected within this timeframe involve a heightened utilization of biologic treatments, a more frequent application of disease-modifying antirheumatic drugs (DMARDs) designed for specific targets, a greater commitment to identifying the disease in its early stages, the advancement of tailored therapeutic strategies, and a more comprehensive incorporation of physical therapy into patient care plans.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11962&type=smp

Ankylosing Spondylitis Market Industry Drivers: What Is Driving Revenue Growth?

The projected expansion of the ankylosing spondylitis market is anticipated to be propelled by the rising occurrence of autoimmune conditions. These conditions encompass a wide array of disorders marked by an aberrant immune system response where the body’s own defenses erroneously attack and harm healthy cells, tissues, and organs. Ankylosing spondylitis, classified as an autoimmune disease, arises when the immune system incorrectly directs its activity towards the body’s own tissues, resulting in inflammation and subsequent damage. While a genetic susceptibility and environmental influences play a role in the pathogenesis of ankylosing spondylitis, a type of autoimmune arthritis predominantly impacting the spinal column and pelvic region, further data underscores this trend. Specifically, the Impact of IBD Report 2023, released in September 2023 by the IBD Clinical and Research Centre in Canada, highlighted that in 2023, inflammatory bowel disease (IBD) affected 825 individuals per 100,000, impacting over 320,000 Canadians. Moreover, with an anticipated annual prevalence increase of 2.44%, it is estimated that by 2035, 1.1% of the Canadian populace, equating to 470,000 individuals, will be managing IBD. Consequently, the escalating rates of autoimmune diseases are poised to fuel the forthcoming growth trajectory of the ankylosing spondylitis market.

Ankylosing Spondylitis Market Segmentation And Category Breakdown

The ankylosing spondylitis market covered in this report is segmented –

1) By Treatment Type: Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biological Therapies, Steroids, Physical Therapies, Surgery

2) By Molecule: Biologics, Biosimilar, Small Molecules

3) By Route Of Administration: Parenteral, Oral, Other Routes

4) By Application: Juveniles, Adults

5) By End User: Hospitals, Clinics

Subsegments:

1) By Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Over-The-Counter NSAIDs, Prescription NSAIDs

2) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional DMARDs, Targeted DMARDs

3) By Biological Therapies: TNF Inhibitors, IL-17 Inhibitors

4) By Steroids: Oral Steroids, Injectable Steroids

5) By Physical Therapies: Physiotherapy, Exercise Programs

6) By Surgery: Joint Replacement Surgery, Spinal Surgery

#Ankylosing Spondylitis Market Growth Trends: What Is Influencing The Future Outlook?

Within the ankylosing spondylitis market, leading corporations are concentrating their efforts on creating cutting-edge biologic treatments, including biosimilars, with the aims of improving patient accessibility, lowering healthcare expenditures, and offering established delivery methods. These biosimilars are medications that utilize the same active components as original biologic drugs but are designed to be just as effective and safe. To illustrate, in August 2025, Amgen Biotechnology Singapore, a biotechnology enterprise situated in Singapore, secured approval for its adalimumab biosimilar, known as Amgevita, available in both a 40 mg/0.4 mL autoinjector and a 20 mg/0.2 mL prefilled syringe. This treatment is prescribed to alleviate the signs and symptoms experienced by adult individuals suffering from active ankylosing spondylitis who have not responded adequately to standard treatments. This approach facilitates well-known administration pathways, capitalizes on a recognized active compound, and introduces a more economically viable choice within the biologics sector.

Ankylosing Spondylitis Market Competitive Analysis Of Major Industry Participants

Major companies operating in the ankylosing spondylitis market are Pfizer Inc., Johnson & Johnson Pvt. Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Viatris Inc., Astellas Pharma Inc., AstraZeneca plc, UCB Inc., Cipla Inc., Zydus Lifesciences Limited, Celltrion Inc., Hetero Labs Ltd., Janssen Biotech Inc., Reliance Life Sciences Pvt. Ltd.

Access The Complete Ankylosing Spondylitis Market Report:

https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report

Ankylosing Spondylitis Market Geographic Landscape: Which Region Dominates Industry Growth?

North America was the largest region in the ankylosing spondylitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ankylosing spondylitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Ankylosing Spondylitis Market Size Forecast: How Large Could The Market Become By 2030?

The ankylosing spondylitis market demonstrated robust expansion recently, with projections indicating a rise from $6.34 billion in 2025 to $6.85 billion in 2026, reflecting a compound annual growth rate of 8.0%. This historical growth trajectory was underpinned by heightened diagnostic recognition, broader accessibility to non-steroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs), enhanced provision of specialized rheumatology care, expanded access to hospital-based treatments, and the increasing utilization of diagnostic imaging for tracking disease progression.

The ankylosing spondylitis market is poised for substantial expansion over the coming years, projecting a rise to $9.42 billion by 2030 with a compound annual growth rate of 8.3%. This anticipated increase during the forecast period is propelled by several key factors, including a greater acceptance of biologic and biosimilar treatments, an escalating emphasis on individualized medical care, the broadening of sophisticated biologic drug development, a growing need for sustained management of the condition, and increased funding allocated to autoimmune disease research. Prominent developments expected within this timeframe involve a heightened utilization of biologic treatments, a more frequent application of disease-modifying antirheumatic drugs (DMARDs) designed for specific targets, a greater commitment to identifying the disease in its early stages, the advancement of tailored therapeutic strategies, and a more comprehensive incorporation of physical therapy into patient care plans.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11962&type=smp

Ankylosing Spondylitis Market Industry Drivers: What Is Driving Revenue Growth?

The projected expansion of the ankylosing spondylitis market is anticipated to be propelled by the rising occurrence of autoimmune conditions. These conditions encompass a wide array of disorders marked by an aberrant immune system response where the body’s own defenses erroneously attack and harm healthy cells, tissues, and organs. Ankylosing spondylitis, classified as an autoimmune disease, arises when the immune system incorrectly directs its activity towards the body’s own tissues, resulting in inflammation and subsequent damage. While a genetic susceptibility and environmental influences play a role in the pathogenesis of ankylosing spondylitis, a type of autoimmune arthritis predominantly impacting the spinal column and pelvic region, further data underscores this trend. Specifically, the Impact of IBD Report 2023, released in September 2023 by the IBD Clinical and Research Centre in Canada, highlighted that in 2023, inflammatory bowel disease (IBD) affected 825 individuals per 100,000, impacting over 320,000 Canadians. Moreover, with an anticipated annual prevalence increase of 2.44%, it is estimated that by 2035, 1.1% of the Canadian populace, equating to 470,000 individuals, will be managing IBD. Consequently, the escalating rates of autoimmune diseases are poised to fuel the forthcoming growth trajectory of the ankylosing spondylitis market.

Ankylosing Spondylitis Market Segmentation And Category Breakdown

The ankylosing spondylitis market covered in this report is segmented –

1) By Treatment Type: Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biological Therapies, Steroids, Physical Therapies, Surgery

2) By Molecule: Biologics, Biosimilar, Small Molecules

3) By Route Of Administration: Parenteral, Oral, Other Routes

4) By Application: Juveniles, Adults

5) By End User: Hospitals, Clinics

Subsegments:

1) By Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Over-The-Counter NSAIDs, Prescription NSAIDs

2) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional DMARDs, Targeted DMARDs

3) By Biological Therapies: TNF Inhibitors, IL-17 Inhibitors

4) By Steroids: Oral Steroids, Injectable Steroids

5) By Physical Therapies: Physiotherapy, Exercise Programs

6) By Surgery: Joint Replacement Surgery, Spinal Surgery

#Ankylosing Spondylitis Market Growth Trends: What Is Influencing The Future Outlook?

Within the ankylosing spondylitis market, leading corporations are concentrating their efforts on creating cutting-edge biologic treatments, including biosimilars, with the aims of improving patient accessibility, lowering healthcare expenditures, and offering established delivery methods. These biosimilars are medications that utilize the same active components as original biologic drugs but are designed to be just as effective and safe. To illustrate, in August 2025, Amgen Biotechnology Singapore, a biotechnology enterprise situated in Singapore, secured approval for its adalimumab biosimilar, known as Amgevita, available in both a 40 mg/0.4 mL autoinjector and a 20 mg/0.2 mL prefilled syringe. This treatment is prescribed to alleviate the signs and symptoms experienced by adult individuals suffering from active ankylosing spondylitis who have not responded adequately to standard treatments. This approach facilitates well-known administration pathways, capitalizes on a recognized active compound, and introduces a more economically viable choice within the biologics sector.

Ankylosing Spondylitis Market Competitive Analysis Of Major Industry Participants

Major companies operating in the ankylosing spondylitis market are Pfizer Inc., Johnson & Johnson Pvt. Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Viatris Inc., Astellas Pharma Inc., AstraZeneca plc, UCB Inc., Cipla Inc., Zydus Lifesciences Limited, Celltrion Inc., Hetero Labs Ltd., Janssen Biotech Inc., Reliance Life Sciences Pvt. Ltd.

Access The Complete Ankylosing Spondylitis Market Report:

https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report

Ankylosing Spondylitis Market Geographic Landscape: Which Region Dominates Industry Growth?

North America was the largest region in the ankylosing spondylitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ankylosing spondylitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Projected Increase In Market Value Of The Ankylosing Spondylitis Market During 2026–2030?

The ankylosing spondylitis market has demonstrated significant expansion in recent years. It is anticipated to increase from $6.34 billion in 2025 to $6.85 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.0%. This historic growth can be attributed to factors such as heightened diagnostic awareness, greater access to NSAIDs and DMARDs, an increase in specialist rheumatology services, wider availability of hospital-based treatment, and the expanding utilization of imaging for monitoring disease.

The ankylosing spondylitis market is anticipated to show significant expansion in the coming years. It is projected to reach $9.42 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.3%. This projected growth can be attributed to the increasing uptake of biologics and biosimilars, a heightened emphasis on personalized medicine, the development of advanced biologic pipelines, a rising demand for comprehensive long-term disease management, and increased funding for autoimmune research. Prominent trends expected during this forecast period involve a broader adoption of biologic therapies, an elevated use of targeted DMARDs, a stronger focus on early disease detection, the broadening of personalized treatment strategies, and a more integrated approach to physical therapy programs.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report

Which Important Drivers Are Guiding The Ankylosing Spondylitis Market Growth?

The ankylosing spondylitis market is set for growth owing to the escalating occurrence of autoimmune diseases. Autoimmune disorders represent a broad spectrum of conditions where the immune system exhibits an abnormal response, erroneously attacking and causing harm to healthy cells, tissues, and organs within the body. Specifically, conditions like ankylosing spondylitis manifest when the immune system incorrectly targets the body’s own tissues, initiating inflammation and subsequent damage. Both genetic predispositions and environmental elements play a role in the onset of ankylosing spondylitis, which is a type of autoimmune arthritis primarily affecting the spine and pelvis. For instance, in September 2023, the Impact of IBD Report 2023, published by the IBD Clinical and Research Centre (a Canada-based organization focused on enhancing the lives of patients with Crohn’s disease and ulcerative colitis), reported a prevalence of 825 per 100,000 in 2023, indicating that over 320,000 individuals in Canada have inflammatory bowel disease (IBD). With an anticipated annual increase in prevalence of 2.44%, projections suggest that 1.1% of the population, or 470,000 Canadians, will be living with IBD by 2035. Thus, the rising incidence of autoimmune diseases is poised to propel the future expansion of the ankylosing spondylitis market.

How Is The Ankylosing Spondylitis Market Organized By Segment Classification?

The ankylosing spondylitis market covered in this report is segmented –

1) By Treatment Type: Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biological Therapies, Steroids, Physical Therapies, Surgery

2) By Molecule: Biologics, Biosimilar, Small Molecules

3) By Route Of Administration: Parenteral, Oral, Other Routes

4) By Application: Juveniles, Adults

5) By End User: Hospitals, Clinics

Subsegments:

1) By Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Over-The-Counter NSAIDs, Prescription NSAIDs

2) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional DMARDs, Targeted DMARDs

3) By Biological Therapies: TNF Inhibitors, IL-17 Inhibitors

4) By Steroids: Oral Steroids, Injectable Steroids

5) By Physical Therapies: Physiotherapy, Exercise Programs

6) By Surgery: Joint Replacement Surgery, Spinal Surgery

What Trends Are Influencing The Evolution Of The Ankylosing Spondylitis Market?

Major companies within the ankylosing spondylitis market are focusing on creating advanced biologic solutions, such as biosimilars, to improve patient accessibility, lower treatment expenses, and offer accustomed administration options. These biosimilars are therapeutics that utilize the proven active ingredients of reference biologics while maintaining comparable efficacy and safety characteristics. For instance, in August 2025, Amgen Biotechnology Singapore, a Singapore-based biotech firm, gained approval for its biosimilar adalimumab (Amgevita), offered in both a 40 mg/0.4 mL autoinjector and a 20 mg/0.2 mL prefilled syringe. This particular therapy is indicated for reducing indicators and symptoms in adult patients with active ankylosing spondylitis who have had an inadequate response to standard therapy, thereby providing familiar administration methods, leveraging a recognized active ingredient, and presenting a more affordable alternative in the biologics domain.

Who Are The Industry Participants Involved In The Ankylosing Spondylitis Market?

Major companies operating in the ankylosing spondylitis market are Pfizer Inc., Johnson & Johnson Pvt. Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Viatris Inc., Astellas Pharma Inc., AstraZeneca plc, UCB Inc., Cipla Inc., Zydus Lifesciences Limited, Celltrion Inc., Hetero Labs Ltd., Janssen Biotech Inc., Reliance Life Sciences Pvt. Ltd.

Get The Full Ankylosing Spondylitis Market Report:

https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report

Which Region Has The Greatest Market Share In The Ankylosing Spondylitis Market?

North America was the largest region in the ankylosing spondylitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ankylosing spondylitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Ankylosing Spondylitis Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report

Browse Through More Reports Similar to the Global Ankylosing Spondylitis Market 2026, By The Business Research Company

Osteoarthritis Market Report 2026

https://www.thebusinessresearchcompany.com/report/osteoarthritis-global-market-report

Cervical Spondylosis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/cervical-spondylosis-treatment-global-market-report

Axial Spondyloarthritis Axspa Market Report 2026

https://www.thebusinessresearchcompany.com/report/axial-spondyloarthritis-axspa-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Projected Increase In Market Value Of The Ankylosing Spondylitis Market During 2026–2030?

The ankylosing spondylitis market has demonstrated significant expansion in recent years. It is anticipated to increase from $6.34 billion in 2025 to $6.85 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.0%. This historic growth can be attributed to factors such as heightened diagnostic awareness, greater access to NSAIDs and DMARDs, an increase in specialist rheumatology services, wider availability of hospital-based treatment, and the expanding utilization of imaging for monitoring disease.

The ankylosing spondylitis market is anticipated to show significant expansion in the coming years. It is projected to reach $9.42 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.3%. This projected growth can be attributed to the increasing uptake of biologics and biosimilars, a heightened emphasis on personalized medicine, the development of advanced biologic pipelines, a rising demand for comprehensive long-term disease management, and increased funding for autoimmune research. Prominent trends expected during this forecast period involve a broader adoption of biologic therapies, an elevated use of targeted DMARDs, a stronger focus on early disease detection, the broadening of personalized treatment strategies, and a more integrated approach to physical therapy programs.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report

Which Important Drivers Are Guiding The Ankylosing Spondylitis Market Growth?

The ankylosing spondylitis market is set for growth owing to the escalating occurrence of autoimmune diseases. Autoimmune disorders represent a broad spectrum of conditions where the immune system exhibits an abnormal response, erroneously attacking and causing harm to healthy cells, tissues, and organs within the body. Specifically, conditions like ankylosing spondylitis manifest when the immune system incorrectly targets the body’s own tissues, initiating inflammation and subsequent damage. Both genetic predispositions and environmental elements play a role in the onset of ankylosing spondylitis, which is a type of autoimmune arthritis primarily affecting the spine and pelvis. For instance, in September 2023, the Impact of IBD Report 2023, published by the IBD Clinical and Research Centre (a Canada-based organization focused on enhancing the lives of patients with Crohn’s disease and ulcerative colitis), reported a prevalence of 825 per 100,000 in 2023, indicating that over 320,000 individuals in Canada have inflammatory bowel disease (IBD). With an anticipated annual increase in prevalence of 2.44%, projections suggest that 1.1% of the population, or 470,000 Canadians, will be living with IBD by 2035. Thus, the rising incidence of autoimmune diseases is poised to propel the future expansion of the ankylosing spondylitis market.

How Is The Ankylosing Spondylitis Market Organized By Segment Classification?

The ankylosing spondylitis market covered in this report is segmented –

1) By Treatment Type: Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biological Therapies, Steroids, Physical Therapies, Surgery

2) By Molecule: Biologics, Biosimilar, Small Molecules

3) By Route Of Administration: Parenteral, Oral, Other Routes

4) By Application: Juveniles, Adults

5) By End User: Hospitals, Clinics

Subsegments:

1) By Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Over-The-Counter NSAIDs, Prescription NSAIDs

2) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional DMARDs, Targeted DMARDs

3) By Biological Therapies: TNF Inhibitors, IL-17 Inhibitors

4) By Steroids: Oral Steroids, Injectable Steroids

5) By Physical Therapies: Physiotherapy, Exercise Programs

6) By Surgery: Joint Replacement Surgery, Spinal Surgery

What Trends Are Influencing The Evolution Of The Ankylosing Spondylitis Market?

Major companies within the ankylosing spondylitis market are focusing on creating advanced biologic solutions, such as biosimilars, to improve patient accessibility, lower treatment expenses, and offer accustomed administration options. These biosimilars are therapeutics that utilize the proven active ingredients of reference biologics while maintaining comparable efficacy and safety characteristics. For instance, in August 2025, Amgen Biotechnology Singapore, a Singapore-based biotech firm, gained approval for its biosimilar adalimumab (Amgevita), offered in both a 40 mg/0.4 mL autoinjector and a 20 mg/0.2 mL prefilled syringe. This particular therapy is indicated for reducing indicators and symptoms in adult patients with active ankylosing spondylitis who have had an inadequate response to standard therapy, thereby providing familiar administration methods, leveraging a recognized active ingredient, and presenting a more affordable alternative in the biologics domain.

Who Are The Industry Participants Involved In The Ankylosing Spondylitis Market?

Major companies operating in the ankylosing spondylitis market are Pfizer Inc., Johnson & Johnson Pvt. Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Viatris Inc., Astellas Pharma Inc., AstraZeneca plc, UCB Inc., Cipla Inc., Zydus Lifesciences Limited, Celltrion Inc., Hetero Labs Ltd., Janssen Biotech Inc., Reliance Life Sciences Pvt. Ltd.

Get The Full Ankylosing Spondylitis Market Report:

https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report

Which Region Has The Greatest Market Share In The Ankylosing Spondylitis Market?

North America was the largest region in the ankylosing spondylitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ankylosing spondylitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Ankylosing Spondylitis Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report

Browse Through More Reports Similar to the Global Ankylosing Spondylitis Market 2026, By The Business Research Company

Osteoarthritis Market Report 2026

https://www.thebusinessresearchcompany.com/report/osteoarthritis-global-market-report

Cervical Spondylosis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/cervical-spondylosis-treatment-global-market-report

Axial Spondyloarthritis Axspa Market Report 2026

https://www.thebusinessresearchcompany.com/report/axial-spondyloarthritis-axspa-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Projected Increase In Market Value Of The Ankylosing Spondylitis Market During 2026–2030?

The ankylosing spondylitis market has demonstrated significant expansion in recent years. It is anticipated to increase from $6.34 billion in 2025 to $6.85 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.0%. This historic growth can be attributed to factors such as heightened diagnostic awareness, greater access to NSAIDs and DMARDs, an increase in specialist rheumatology services, wider availability of hospital-based treatment, and the expanding utilization of imaging for monitoring disease.

The ankylosing spondylitis market is anticipated to show significant expansion in the coming years. It is projected to reach $9.42 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.3%. This projected growth can be attributed to the increasing uptake of biologics and biosimilars, a heightened emphasis on personalized medicine, the development of advanced biologic pipelines, a rising demand for comprehensive long-term disease management, and increased funding for autoimmune research. Prominent trends expected during this forecast period involve a broader adoption of biologic therapies, an elevated use of targeted DMARDs, a stronger focus on early disease detection, the broadening of personalized treatment strategies, and a more integrated approach to physical therapy programs.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report

Which Important Drivers Are Guiding The Ankylosing Spondylitis Market Growth?

The ankylosing spondylitis market is set for growth owing to the escalating occurrence of autoimmune diseases. Autoimmune disorders represent a broad spectrum of conditions where the immune system exhibits an abnormal response, erroneously attacking and causing harm to healthy cells, tissues, and organs within the body. Specifically, conditions like ankylosing spondylitis manifest when the immune system incorrectly targets the body’s own tissues, initiating inflammation and subsequent damage. Both genetic predispositions and environmental elements play a role in the onset of ankylosing spondylitis, which is a type of autoimmune arthritis primarily affecting the spine and pelvis. For instance, in September 2023, the Impact of IBD Report 2023, published by the IBD Clinical and Research Centre (a Canada-based organization focused on enhancing the lives of patients with Crohn’s disease and ulcerative colitis), reported a prevalence of 825 per 100,000 in 2023, indicating that over 320,000 individuals in Canada have inflammatory bowel disease (IBD). With an anticipated annual increase in prevalence of 2.44%, projections suggest that 1.1% of the population, or 470,000 Canadians, will be living with IBD by 2035. Thus, the rising incidence of autoimmune diseases is poised to propel the future expansion of the ankylosing spondylitis market.

How Is The Ankylosing Spondylitis Market Organized By Segment Classification?

The ankylosing spondylitis market covered in this report is segmented –

1) By Treatment Type: Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biological Therapies, Steroids, Physical Therapies, Surgery

2) By Molecule: Biologics, Biosimilar, Small Molecules

3) By Route Of Administration: Parenteral, Oral, Other Routes

4) By Application: Juveniles, Adults

5) By End User: Hospitals, Clinics

Subsegments:

1) By Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Over-The-Counter NSAIDs, Prescription NSAIDs

2) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional DMARDs, Targeted DMARDs

3) By Biological Therapies: TNF Inhibitors, IL-17 Inhibitors

4) By Steroids: Oral Steroids, Injectable Steroids

5) By Physical Therapies: Physiotherapy, Exercise Programs

6) By Surgery: Joint Replacement Surgery, Spinal Surgery

What Trends Are Influencing The Evolution Of The Ankylosing Spondylitis Market?

Major companies within the ankylosing spondylitis market are focusing on creating advanced biologic solutions, such as biosimilars, to improve patient accessibility, lower treatment expenses, and offer accustomed administration options. These biosimilars are therapeutics that utilize the proven active ingredients of reference biologics while maintaining comparable efficacy and safety characteristics. For instance, in August 2025, Amgen Biotechnology Singapore, a Singapore-based biotech firm, gained approval for its biosimilar adalimumab (Amgevita), offered in both a 40 mg/0.4 mL autoinjector and a 20 mg/0.2 mL prefilled syringe. This particular therapy is indicated for reducing indicators and symptoms in adult patients with active ankylosing spondylitis who have had an inadequate response to standard therapy, thereby providing familiar administration methods, leveraging a recognized active ingredient, and presenting a more affordable alternative in the biologics domain.

Who Are The Industry Participants Involved In The Ankylosing Spondylitis Market?

Major companies operating in the ankylosing spondylitis market are Pfizer Inc., Johnson & Johnson Pvt. Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Viatris Inc., Astellas Pharma Inc., AstraZeneca plc, UCB Inc., Cipla Inc., Zydus Lifesciences Limited, Celltrion Inc., Hetero Labs Ltd., Janssen Biotech Inc., Reliance Life Sciences Pvt. Ltd.

Get The Full Ankylosing Spondylitis Market Report:

https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report

Which Region Has The Greatest Market Share In The Ankylosing Spondylitis Market?

North America was the largest region in the ankylosing spondylitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ankylosing spondylitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Ankylosing Spondylitis Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report

Browse Through More Reports Similar to the Global Ankylosing Spondylitis Market 2026, By The Business Research Company

Osteoarthritis Market Report 2026

https://www.thebusinessresearchcompany.com/report/osteoarthritis-global-market-report

Cervical Spondylosis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/cervical-spondylosis-treatment-global-market-report

Axial Spondyloarthritis Axspa Market Report 2026

https://www.thebusinessresearchcompany.com/report/axial-spondyloarthritis-axspa-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Ankylosing Spondylitis Market From 2026 To 2030?

The ankylosing spondylitis market has recorded strong growth in recent years. It is expected to grow from $6.34 billion in 2025 to $6.85 billion in 2026, at a CAGR of 8.0%. This growth is supported by improved awareness and diagnosis, broader availability of NSAIDs and DMARDs, increased access to rheumatology specialists, expansion of hospital-based treatments, and greater use of imaging technologies for disease monitoring.

The ankylosing spondylitis market is expected to see strong growth, reaching $9.42 billion by 2030 at a CAGR of 8.3%. This growth is driven by increased adoption of biologics and biosimilars, a growing focus on personalized medicine, expansion of advanced biologic pipelines, rising demand for long-term disease management, and increased investment in autoimmune research. Major trends include wider use of biologic therapies, growing adoption of targeted DMARDs, increased emphasis on early diagnosis, expansion of personalized treatment strategies, and stronger integration of physical therapy programs.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11962&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Ankylosing Spondylitis Market?

The rising occurrence of autoimmune diseases is expected to support the growth of the ankylosing spondylitis market going forward. Autoimmune diseases involve abnormal immune responses where the body attacks its own tissues, leading to inflammation and damage. Ankylosing spondylitis, a type of autoimmune arthritis affecting the spine and pelvis, develops due to a combination of genetic and environmental factors. For instance, in September 2023, the Impact of IBD Report 2023 by the IBD Clinical and Research Centre, a Canada-based organization, indicated that over 320,000 Canadians were living with inflammatory bowel disease (IBD) in 2023, with a prevalence of 825 per 100,000, projected to rise annually by 2.44% to reach 470,000 cases (1.1% of the population) by 2035. Thus, the increasing incidence of autoimmune diseases is driving the ankylosing spondylitis market.

Which Segments Are Included In The Analysis Of The Ankylosing Spondylitis Market?

The ankylosing spondylitis market covered in this report is segmented –

1) By Treatment Type: Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biological Therapies, Steroids, Physical Therapies, Surgery

2) By Molecule: Biologics, Biosimilar, Small Molecules

3) By Route Of Administration: Parenteral, Oral, Other Routes

4) By Application: Juveniles, Adults

5) By End User: Hospitals, Clinics

Subsegments:

1) By Painkillers And Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Over-The-Counter NSAIDs, Prescription NSAIDs

2) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional DMARDs, Targeted DMARDs

3) By Biological Therapies: TNF Inhibitors, IL-17 Inhibitors

4) By Steroids: Oral Steroids, Injectable Steroids

5) By Physical Therapies: Physiotherapy, Exercise Programs

6) By Surgery: Joint Replacement Surgery, Spinal Surgery

Which Trends Are Impacting The Growth Of The Ankylosing Spondylitis Market?

Key companies in the ankylosing spondylitis market are focusing on advanced biologic treatments such as biosimilars to improve patient access, lower costs, and provide familiar treatment options. Biosimilars use established active ingredients from reference biologics while maintaining comparable safety and effectiveness. For instance, in August 2025, Amgen Biotechnology Singapore received approval for its biosimilar adalimumab (Amgevita) in 40 mg/0.4 mL autoinjector and 20 mg/0.2 mL prefilled syringe formats. This treatment is designed for adults with active ankylosing spondylitis who have not responded adequately to standard therapies, offering a cost-effective alternative with convenient administration.

Which Key Industry Participants Are Active In The Ankylosing Spondylitis Market?

Major companies operating in the ankylosing spondylitis market are Pfizer Inc., Johnson & Johnson Pvt. Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Viatris Inc., Astellas Pharma Inc., AstraZeneca plc, UCB Inc., Cipla Inc., Zydus Lifesciences Limited, Celltrion Inc., Hetero Labs Ltd., Janssen Biotech Inc., Reliance Life Sciences Pvt. Ltd.

Read the full ankylosing spondylitis market report here:

https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report

What Are The Leading Geographic Regions In The Ankylosing Spondylitis Market?

North America was the largest region in the ankylosing spondylitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ankylosing spondylitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Ankylosing Spondylitis Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=11962&type=smp

Browse Through More Reports Similar to the Global Ankylosing Spondylitis Market 2026, By The Business Research Company

Cervical Spondylosis Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/cervical-spondylosis-treatment-global-market-report

Axial Spondyloarthritis Axspa Global Market Report

https://www.thebusinessresearchcompany.com/report/axial-spondyloarthritis-axspa-global-market-report

Osteoarthritis Global Market Report

https://www.thebusinessresearchcompany.com/report/osteoarthritis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model